Apixaban in Obese Patients

Please use landscape view or desktop screen to view the content.

Retrospective subgroup analysis of the ARISTOPHANES study using pooled data from fee-for-service CMS Medicare database and 4 US commercial claims databases (PharMetrics, MarketScan^®, Optum™, and Humana) of 88,461 obese patients with NVAF newly prescribed apixaban, dabigatran, rivaroxaban, or warfarin
- Excluded patients with prior use of an OAC, use of OAC for indication other than AF, or presence of valvular heart disease
Ratio of 1:1 PSM* was applied to balance demographics and clinical characteristics among the 3 NOACs versus warfarin and 3 NOACs versus NOAC comparator groups
Rates of hospitalization due to stroke/SE (including ischemic stroke, hemorrhagic stroke, and SE) and major bleeding (including GI bleeding, ICH, and bleeding at other key sites^†) were measured from the first Rx date (January 1, 2013 to September 30, 2015) to earliest of treatment D/C, treatment switch, death^‡, end of continuous medical or pharmacy plan enrollment, or the end of study (September 30, 2015)

1|2

*Patients were matched 1:1 in each dataset based on the propensity scores generated by the logistic regression using demographics, Charlson Comorbidity Index scores, comorbidities, and baseline co-medications.
^†Includes bleeding at genitourinary, respiratory tract, and ocular sites.
^‡Only inpatient death information was available for the commercial databases and all-cause death information for CMS Medicare database.

AF, atrial fibrillation; ARISTOPHANES, Anticoagulants for Reduction in Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients; BMI, body mass index;
CMS, US Centers for Medicare & Medicaid Services; D/C, discontinuation; GI, gastrointestinal; ICH, intracranial hemorrhage; NOAC, non-vitamin K antagonist oral anticoagulant;
NVAF, nonvalvular atrial fibrillation; OAC, oral anticoagulant; PSM, propensity score matching; SE, systemic embolism; US, United States.

Methods1

Methods¹